Wednesday 18 November 2026 The business of healthcare in India, the UK and the Gulf
The Healthcare Daily
Get The Handover

Archive

Bharat Biotech's Covaxin gets approval for Phase 2, 3 trials for 2-18-year-olds

THD NewsDesk, New Delhi: Bharat Biotech's Covid-19 vaccine "Covaxin" has been approved for the phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

Follow on Google News (opens in a new tab)

From the archive. Published on 12 May 2021 and not updated since. Figures and job titles may have changed.

THD NewsDesk, New Delhi: Bharat Biotech’s Covid-19 vaccine “Covaxin” has been approved for the phase II/III clinical trial on those aged between two to 18 years.

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organization (CDSCO) had a discussion upon Hyderabad-based Bharat Biotech’s application seeking permission to conduct phase II/III clinical trials. It aimed at scrutinizing the the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.

A source said,

“After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommendations to the CDSCO before proceeding to phase III part of the study.” 

Earlier the proposal was discussed on February 24 and the firm was asked to submit a revised clinical trial protocol.

Covaxin, a product of Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in India’s ongoing Covid-19 vaccination drive and till now have been given to the people above 45 years in the first phase and above 18 years in the second phase. If this trial proves to be successful, the vaccination drive of the age group below 18 could also be started soon.

Source: Deccan Herald

The Healthcare Daily. We report from primary sources and list them on every story.

Read our editorial policy

The Handover

In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.

One email each weekday after launch. Unsubscribe at any time.

Search The Healthcare Daily

Saved stories

Kept in this browser only. There is no account and nothing is sent to us.